Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Omiganan: Phase III delayed

September 22, 2008 7:00 AM UTC

Migenix said that partner Cutanea would delay the start of Phase III testing of topical Omiganan to 2H09 from this half. Cutanea has exclusive rights to Omiganan for dermatological applications from M...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article